Description: Recap of the Health Policy Summit held in honor of Health Affairs’ 25th anniversary.

Description: Update on the SOA Health Section's Public Health Task Force's comment on Health People 2030.

Description: Article summarizes the sessions of the 2011 SOA Health Meeting held in Boston.

Description: The big event of 2023 is the launch of multiple Humira biosimilars, which began in January with the arrival of Amgen’s Amjevita on the market. The launch of Amjevita kicks off the process of changing the specialty drug marketplace in the United States. The expectation of the full impact of this big event is very hopeful, but there is still uncertainty several months after its beginning. Humira is the highest-selling drug in the world and has been since 2013 (Figure 1)—except for when COVID-19 projects temporarily surpassed it. The world is eagerly awaiting the launch of multiple biosimilar drugs to compete with Humira and hopefully bring more competitive pricing to the benefit of payers and patients everywhere.

Description: New and ongoing health projects at the Academy. From Health Watch, May 2008, Issue NO. 58

Description: Part 1 of a 2-part series exploring implementation issues for the Mental Health Parity and Addiction Equity Act of 2008 MHPAEA. Part 2 addresses the new enforcement safe harbor, how the regulations could impact the business of behavioral health care and the impending decisions for payors, employers, providers, and insureds.

Description: Article presents a summary of the AAA's Health Practice Council Activities including input for PPACA and various work groups.

Description: Discussion of Alternative or Integrative Care - Fundamental themes, market demand, recent activity, developing an alternative care program, pricing benefits Issue No. 34.

Description: Ian Duncan argues that there is no crisis in American health care.

Description: This article summarizes a joint SOA/Kaiser Family Foundation initiative focused on addressing the rising cost of health care in the United States.